1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsStrategic Growth Loan (SGL) is sponsored by North Carolina Biotechnology Center (NCBiotech). The SGL supplements investments with angel or venture capital to fund life sciences companies that have established technical proof-of-concept and require further support to accelerate growth. This could apply to more developed cancer immunotherapy projects.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Type: Loan | Category: Business Loans The Strategic Growth Loan (SGL) program helps North Carolina life science companies reach specific and meaningful milestones that enable follow-on equity investment and/or commercialization. SGL awards of $350,000 to $650,000 requre an equity investment match of an equal or greater amount from a qualified investor or investor syndicate.
Higher value awards (up to $650,000) are reserved for exceptionally well-qualified applicants who have a matching investment from a top-tier life science investment group. To be eligible to apply for the SGL, it must meet the minimum criteria below: * Maintain a significant operating presence in North Carolina. All applicants are required to establish and maintain a business registration with the NC Secretary of State.
Preference will be given to companies that are engaged in significant research, product development, or manufacturing activity in North Carolina. * Be engaged in _life sciences_ research, development, or manufacturing to develop a product or technology with commercial potential. * If company has previously been awarded an NCBiotech SRL, all SRL milestones have been successfully met.
If company is a first-time applicant to the loan program, they must show evidence that significant traction has been achieved in meeting development milestones (e.g., strong advanced preclinical data or early clinical data). * Have a well-rounded and dedicated management team and a comprehensive business plan and/or model for commercializing the product.
* Own or have a _valid license(s)_ to the relevant intellectual property necessary for successful product commercialization and a well-developed IP strategy. * Have obtained a matching investment (minimally, a commitment for a near-term investment) from an accredited investor or investor syndicate, at least equal in value to the amount being sought under the SGL.
Matching investor(s) should have significant life sciences investing experience and is expected to conduct formal due diligence. **NCBiotech determines compliance with these requirements in its sole discretion on a case-by-case basis. ** _**Pre-Application**_**:** Pre-applications are accepted by invitation only following qualification of the applicant’s eligibility.
Applicant eligibility is assessed by meeting with one or more members of the Investments team, after which qualified applicants are invited to apply into the nearest quarterly round. Pre-applications should describe the company’s management, technology, proposed project, and budget.
_**Full Application**_**:** Following competitive review of pre-applications, the strongest applicants will be invited to submit a full application further describing the company’s commercial opportunity, development and financing strategies, and other supporting documentation.
_**Review and Approval**_**:** Following competitive review of full applications, the strongest applicants will enter due diligence with a member of the Investments team to further evaluate the team, technology, and commercial potential. Final funding recommendations will be presented to NCBiotech senior leadership and a subcommittee of its Board of Directors for final review and approval.
**Application Deadlines:** The Strategic Growth Loan consists of: * A senior loan with favorable terms including: * Five-year, fixed-term balloon note * Interest rate equal to the current Wall Street Prime rate plus 2%, with a maximum rate of 7% * A warrant to purchase company stock **For all SGL inquiries, please contact loans@ncbiotech.
org** Type: Loan | Category: Business Loans **Maximum Award:** $650,000 **Contact:** loans@ncbiotech. org
According to the current listing, eligibility includes: Life sciences companies in North Carolina that have established technical proof-of-concept and attracted angel or venture capital investments. Confirm the full requirements in the official notice before applying.
The current listing shows $350,000 to $650,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Strategic Growth Loan (SGL) is funded by North Carolina Biotechnology Center (NCBiotech). Verify program details on the funder's official page before applying.
This opportunity targets applicants in North Carolina. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The Hewlett Foundation's Emerging Technology and Security Initiative commits $20 million a year through 2031 across AI, biotechnology, and quantum computing security. Its 2026 exploratory grants went to thirteen named institutions with no open call. For organizations outside that list, the path in runs through a specific set of moves — and the five-year term starting in 2027 is the window.
Read articleThe Energy Department's first Genesis Mission SBIR/STTR Phase I solicitation offers roughly 40 awards of up to $250,000 against $10 million — but you cannot submit a full application anymore. A four-question, 700-word pitch now decides who gets to apply, there is no Direct to Phase II path for new entrants, and the $147.4 million Phase II pool is closed to everyone who has never won a DOE award.
Read articleDARPA's FY26 SBIR/STTR Release 5 pre-released August 5, 2026, opens August 26, and closes September 23 — a four-week window. Five SBIR topics and one STTR topic span underwater 3D concrete printing, semantic ISR communications, species-agnostic cell culture, open-architecture AUVs, and algorithm-discovery tooling. Here is what each topic funds, why DARPA's new monthly cadence changes how small businesses should plan, and how to use the three-week pre-release to talk to topic authors before the clock starts.
Read article